CUSIP: 829399104
Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COMMON
-
Total 13F shares
-
18,100,292
-
Share change
-
-3,227,261
-
Total reported value
-
$12,125,820
-
Put/Call ratio
-
135%
-
Price per share
-
$0.67
-
Number of holders
-
31
-
Value change
-
-$3,812,645
-
Number of buys
-
7
-
Number of sells
-
27
Quarterly Holders Quick Answers
What is CUSIP 829399104?
CUSIP 829399104 identifies SIOX - SIO GENE THERAPIES INC - COMMON in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2022
-
Previous quarter:
Q4 2021
Recent filing periods for CUSIP 829399104:
Institutional Holders of SIO GENE THERAPIES INC - COMMON (SIOX) as of Q1 2022
As of 31 Mar 2022,
SIO GENE THERAPIES INC - COMMON (SIOX) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,100,292 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, Rubric Capital Management LP, VANGUARD GROUP INC, Hudson Bay Capital Management LP, Cladis Investment Advisory, LLC, Prosight Management, LP, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, and Clearline Capital LP.
This page lists
31
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.